Preempting and preventing drug-induced liver injury

被引：19

作者：

Aithal, Guruprasad P. ^{[1
]}

Daly, Ann K. ^{[2
]}

机构：

[1] Nottingham Univ Hosp Natl Hlth Serv Trust, Nottingham Digest Dis Ctr, Natl Inst Hlth Res Biomed Res Unit, Nottingham, England

[2] Newcastle Univ, Inst Cellular Med, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England

来源：

NATURE GENETICS | 2010年 / 42卷 / 08期

关键词：

NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THERAPEUTIC ARTHRITIS RESEARCH; RANDOMIZED CONTROLLED-TRIAL; HEPATOTOXICITY; EVENT; PATHOGENESIS; LUMIRACOXIB; IBUPROFEN; NAPROXEN; TARGET;

D O I：

10.1038/ng0810-650

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

A new study reports that susceptibility to drug-induced liver injury by the cyclooxygenase 2 (COX-2) inhibitor lumiracoxib is associated with a human lymphocyte antigen (HLA) class II haplotype. This finding suggests that those at risk of hepatotoxicity can be identified by HLA genotyping, raising the possibility that lumiracoxib can be resurrected as a useful drug.

引用

页码：650 / 651

页数：3